The patient received the Johnson & Johnson (Janssen) vaccine elsewhere and was later admitted to the UCHealth emergency department.
AURORA, Colorado – A patient admitted to the University Hospital Emergency Department (UCHealth) with blood clots developed by the Johnson and Johnson (Jansen) vaccine was treated with an alternative blood thinner according to the Centers for Disease Control and Prevention. ), according to the hospital.
> The video above is from a CDC conference where a health panel in the US is pushing for a restart of J&J COVID-1
On April 13, the day the CDC paused the Johnson and Johnson vaccine, a patient suffering from vaccine-induced thrombotic thrombocytopenia (VITT) was brought to UCHealth, the hospital said.
The patient, a woman in her 40s, came to the emergency department 12 days after receiving the Johnson and Johnson vaccine, according to the hospital.
The CDC has warned that these blood clots, which can result from a rare complication of the Johnson and Johnson vaccine, should not be treated with the usual first-line drug, heparin, which can worsen the clots, UCHealth said in a release.
The CDC did not specify which alternative should be used in these cases, UCHealth said. Doctors at the University of Colorado are working quickly to identify the condition and treat the patient with an alternative blood thinner, bivalirudin, the hospital said.
“Our experience shows that these clot reactions are very rare and can be treated,” said R. Todd Clark, MD, lead co-author and assistant professor of emergency medicine at the University of Colorado School of Medicine. “People may feel comfortable getting vaccinated with one of the permitted vaccines, including the J&J vaccine. Vaccination is a critical step in the fight against this pandemic so that we can return to our normal lives. “
“One-dose vaccination will be convenient for patients in our emergency departments who have not yet received the vaccine due to various barriers,” said Dr. Richard Zane, UCHealth’s chief innovation officer and professor and chairman of Emergency Medicine at the Medical Center. Faculty of the University of Colorado. “Although the risk of developing blood clots is extremely rare, we know that this condition can be treated safely. In the very unlikely event that a patient develops VITT, they would be in good hands with a team of people who can treat it. . “
This is the first known case of a patient with VITT treated with an alternative to heparin, following the instructions of the CDC, according to the hospital.
RELATED: Out of 139,000 J&J shots, three reports of clots in Colorado
RELATED: Colorado recommends restarting J&J immediately, some providers choose to take it slowly
SUGGESTED VIDEO: Last of 9NEWS